Journal Home > Volume 3 , Issue 1
Journal of Neurorestoratology 2015, 3(1): 63-71 https://doi.org/10.2147/JN.S74142
Review | Open Access | Issue | Published: 23 March 2015

Clinical neurorestorative progress in stroke

Show Author's Information Liyan Qiao1,*( ),  Jun Lu2,*,  Hongyun Huang3,4,5( )
Department of Neurology, Tsinghua University Yuquan Hospital,
Department of Emergency, 2nd Artillery Hospital,
Center of Neurorestoratology, Beijing Rehabilitation Hospital, Capital Medical University,
Beijing Hongtianji Neuroscience Academy, Beijing,
Neuroscience Institute of Taishan Medical University, Shandong, People’s Republic of China

*These authors are co-first authors

Keywords:
stroke, treatment, cell therapy, cerebral infarction, neurorestorative strategy, neurological function recovery
Cite this article:
Qiao L, Lu J, Huang H. Clinical neurorestorative progress in stroke. Journal of Neurorestoratology, 2015, 3(1): 63-71. https://doi.org/10.2147/JN.S74142
Download citation
EndNote(RIS)
BibTeX

468

Views

33

Downloads

Citations

7

Crossref

10

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Stroke is the second most common single cause of death worldwide, with over five million deaths per year globally. So far, conventional therapy has failed to restore neurological function poststroke. Neurorestorative strategy has provided therapeutic benefit for the treatment of stroke. This review outlines the clinical advances, in which cell-based neurorestorative strategies offer the broadest range of potential treatments for stroke.


menu
Abstract
Full text
Outline
About this article

Clinical neurorestorative progress in stroke

Show Author's information Liyan Qiao1,*( ), Jun Lu2,*, Hongyun Huang3,4,5( )
Department of Neurology, Tsinghua University Yuquan Hospital,
Department of Emergency, 2nd Artillery Hospital,
Center of Neurorestoratology, Beijing Rehabilitation Hospital, Capital Medical University,
Beijing Hongtianji Neuroscience Academy, Beijing,
Neuroscience Institute of Taishan Medical University, Shandong, People’s Republic of China

*These authors are co-first authors

Abstract

Stroke is the second most common single cause of death worldwide, with over five million deaths per year globally. So far, conventional therapy has failed to restore neurological function poststroke. Neurorestorative strategy has provided therapeutic benefit for the treatment of stroke. This review outlines the clinical advances, in which cell-based neurorestorative strategies offer the broadest range of potential treatments for stroke.

Keywords: stroke, treatment, cell therapy, cerebral infarction, neurorestorative strategy, neurological function recovery

References(92)

1.
Victor M, Ropper AH. Adams and Victor’s Principle of Neurology. 7th ed. New York: McGraw-Hill; 2001.
2.
Howard G, Goff DC. Population shifts and the future of stroke: forecasts of the future burden of stroke. Ann N Y Acad Sci. 2012;1268:14–20.
DOI Google Scholar
3.
Kirkman MA, Citerio G, Smith M. The intensive care management of acute ischemic stroke: an overview. Intensive Care Med. 2014;40(5):640–653.
DOI Google Scholar
4.
Gopurappilly R, Pal R, Mamidi MK, Dey S, Bhonde R, Das AK. Stem cells in stroke repair: current success and future prospects. CNS Neurol Disord Drug Targets. 2011;10(6):741–756.
DOI Google Scholar
5.
Green AR, Ashwood T. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr Drug Targets CNS Neurol Disord. 2005;4(2):109–118.
DOI Google Scholar
6.
Diener HC, Lees KR, Lyden P, et al; SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II trials. Stroke. 2008;39(6):1751–1758.
DOI Google Scholar
7.
Shuaib A, Lees KR, Lyden P, et al; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–571.
DOI Google Scholar
8.
Parnham MJ, Sies H. The early research and development of ebselen. Biochem Pharmacol. 2013;86(9):1248–1253.
DOI Google Scholar
9.
Azad GK, Tomar RS. Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways. Mol Biol Rep. 2014;41(8):4865–4879.
DOI Google Scholar
10.
He M, Xing S, Yang B, et al. Ebselen attenuates oxidative DNA damage and enhances its repair activity in the thalamus after focal cortical infarction in hypertensive rats. Brain Res. 2007;1181:83–92.
DOI Google Scholar
11.
Wu HY, Tang Y, Gao LY, et al. The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. Eur J Pharmacol. 2014;740:522–531.
DOI Google Scholar
12.
Ishibashi A, Yoshitake Y, Adachi H. Investigation of effect of edaravone on ischemic stroke. Kurume Med J. 2013;60(2):53–57.
DOI Google Scholar
13.
Wu S, Sena E, Egan K, Macleod M, Mead G. Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. Int J Stroke. 2014;9(1):101–106.
DOI Google Scholar
14.
Takenaka K, Kato M, Yamauti K, Hayashi K. Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients. J Stroke Cerebrovasc Dis. 2014;23(10):2748–2752.
DOI Google Scholar
15.
Ogden KK, Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci. 2011;32(12):726–733.
DOI Google Scholar
16.
Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7(8):742–755.
DOI Google Scholar
17.
Dhawan J, Benveniste H, Luo Z, Nawrocky M, Smith SD, Biegon A. A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke. Future Neurol. 2011;6(6):823–834.
DOI Google Scholar
18.
Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke. 2008;39(6):1774–1778.
DOI Google Scholar
19.
Rosenberg G, Bornstein N, Diener HC, Gorelick PB, Shuaib A, Lees K; MACSI investigators. The membrane-activated chelator stroke intervention (MACSI) trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study. Int J Stroke. 2011;6(4):362–367.
DOI Google Scholar
20.
Lees KR, Bornstein N, Diener HC, Gorelick PB, Rosenberg G, Shuaib A; MACSI Investigators. Results of membrane-activated chelator stroke intervention randomized trial of DP-b99 in acute ischemic stroke. Stroke. 2013;44(3):580–584.
DOI Google Scholar
21.
Kohler E, Prentice DA, Bates TR, et al. Intravenous minocycline in acute stroke: a randomized, controlled pilot study and meta-analysis. Stroke. 2013;44(9):2493–2499.
DOI Google Scholar
22.
Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007;69(14):1404–1410.
DOI Google Scholar
23.
Padma Srivastava MV, Bhasin A, Bhatia R, et al. Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial. Neurol India. 2012;60(1):23–28.
DOI Google Scholar
24.
Kalladka D, Muir KW. Brain repair: cell therapy in stroke. Stem Cells Cloning. 2014;7:31–44.
DOI Google Scholar
25.
England TJ, Gibson CL, Bath PM. Granulocyte-colony stimulating factor in experimental stroke and its effects on infarct size and functional outcome: a systematic review. Brain Res Rev. 2009;62(1):71–82.
DOI Google Scholar
26.
Abe K, Yamashita T, Takizawa S, Kuroda S, Kinouchi H, Kawahara N. Stem cell therapy for cerebral ischemia: from basic science to clinical applications. J Cereb Blood Flow Metab. 2012;32(7):1317–1331.
DOI Google Scholar
27.
Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocyte colony-stimulating factor for acute ischaemic stroke: a randomized controlled trial. CMAJ. 2006;174:927–933.
DOI Google Scholar
28.
Zhang JJ, Deng M, Zhang Y, et al. A short-term assessment of recombinant granulocyte-stimulating factor (RHG-CSF) in treatment of acute cerebral infarction. Cerebrovasc Dis. 2006;22:323.
Google Scholar
29.
Sprigg N, Bath PM, Zhao L, et al. Granulocyte-colony stimulating factor mobilises bone marrow stem cells in patients with subacute ischemic stroke: the STEMS pilot randomised controlled trial. Stroke. 2006;37:2979–2983.
DOI Google Scholar
30.
Moriya Y, Mizuma A, Uesugi T, et al. Phase I study of intravenous low-dose granulocyte colony-stimulating factor in acute and subacute ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22(7):1088–1097.
DOI Google Scholar
31.
England TJ, Abaei M, Auer DP, et al. Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the stem cell trial of recovery enhancement after stroke 2 randomized controlled trial. Stroke. 2012;43(2):405–411.
DOI Google Scholar
32.
Ringelstein EB, Thijs V, Norrving B, et al; AXIS 2 Investigators. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for ischemic stroke trial. Stroke. 2013;44(10):2681–2687.
DOI Google Scholar
33.
Mendonça ML, Freitas GR, Silva SA, et al. Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke. Arq Bras Cardiol. 2006;86(1):52–55.
Google Scholar
34.
Moniche F, Gonzalez A, Gonzalez-Marcos JR, et al. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012;43(8):2242–2244.
DOI Google Scholar
35.
Friedrich MA, Martins MP, Araújo MD, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012;21(Suppl 1):S13–S21.
DOI Google Scholar
36.
Savitz SI, Misra V, Kasam M, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011;70(1):59–69.
DOI Google Scholar
37.
Honmou O, Houkin K, Matsunaga T, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011;134(Pt 6):1790–1807.
DOI Google Scholar
38.
Honmou O. Cell therapy for stroke. Rinsho Shinkeigaku. 2013;53(11):1175–1176.
DOI Google Scholar
39.
Bringas ML, Suarez C, Sanchez C, et al. Cognitive changes after stem cell transplantation in a patient with subcortical stroke. BMJ Case Rep. 2011: .
DOI Google Scholar
40.
Suárez-Monteagudo C, Hernández-Ramírez P, Alvarez-González L, et al. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci. 2009;27(3):151–161.
Google Scholar
41.
Battistella V, de Freitas GR, da Fonseca LM, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011;6(1):45–52.
DOI Google Scholar
42.
Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28(6):1099–1106.
DOI Google Scholar
43.
Kim SJ, Moon GJ, Chang WH, Kim YH, Bang OY. STARTING-2 (stem cell application researches and trials in neurology-2) collaborators. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Trials. 2013;14(1):317–328.
DOI Google Scholar
44.
Kondziolka D, Wechsler L, Goldstein S, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000;55:565–569.
DOI Google Scholar
45.
Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005;103(1):38–45.
DOI Google Scholar
46.
Meltzer CC, Kondziolka D, Villemagne VL, et al. Serial [18F] fluorodeoxyglucose positron emission tomography after human neuronal implantation for stroke. Neurosurgery. 2001;49(3):586–591.
DOI Google Scholar
47.
Stilley CS, Ryan CM, Kondziolka D, Bender A, DeCesare S, Wechsler L. Changes in cognitive function after neuronal cell transplantation for basal ganglia stroke. Neurology. 2004;63(7):1320–1322.
DOI Google Scholar
48.
Nelson PT, Kondziolka D, Wechsler L, et al. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. Am J Pathol. 2002;160(4):1201–1206.
DOI Google Scholar
49.
Jiang Y, Zhu W, Zhu J, Wu L, Xu G, Liu X. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery. Cell Transplant. 2013;22(12):2291–2298.
DOI Google Scholar
50.
Liu X, Ye R, Yan T, et al. Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol. 2014;115:92–115.
DOI Google Scholar
51.
Chen DC, Lin SZ, Fan JR, et al. Intracerebral implantation of autologous peripheral blood stem cells in stroke patients: a randomized phase II study. Cell Transplant. 2014; 23(12):1599–1612.
DOI Google Scholar
52.
Wang L, Ji H, Li M, et al. Intrathecal administration of autologous CD34 positive cells in patients with past cerebral infarction: a safety study. ISRN Neurol. 2013;2013:128591.
DOI Google Scholar
53.
Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis. 2005;20(2):101–107.
DOI Google Scholar
54.
Bhasin A, Srivastava MV, Mohanty S, Bhatia R, Kumaran SS, Bose S. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2013;115(7):1003–1108.
DOI Google Scholar
55.
Chen L, Xi H, Huang H, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant. 2013;22(Suppl 1):S83–S91.
DOI Google Scholar
56.
Qiao LY, Huang FJ, Zhao M, et al. A two-year follow-up study of co-transplantation with neural stem/precursor cells and mesenchymal stromal cells in ischemic stroke patients. Cell Transplant. 2014;23(Suppl 1):S65–S72.
DOI Google Scholar
57.
Doycheva D, Shih G, Chen H, Applegate R, Zhang JH, Tang J. Granulocyte-colony stimulating factor in combination with stem cell factor confers greater neuroprotection after hypoxic-ischemic brain damage in the neonatal rats than a solitary treatment. Transl Stroke Res. 2013;4(2):171–178.
DOI Google Scholar
58.
Le Q, Qu Y, Tao Y, Zhu S. Effects of repetitive transcranial magnetic stimulation on hand function recovery and excitability of the motor cortex after stroke: a meta-analysis. Am J Phys Med Rehabil. 2014;93(5):422–430.
DOI Google Scholar
59.
Hosomi K, Kishima H, Oshino S, et al. Cortical excitability changes after high-frequency repetitive transcranial magnetic stimulation for central poststroke pain. Pain. 2013;154(8):1352–1357.
DOI Google Scholar
60.
Meinzer M, Lindenberg R, Sieg MM, Nachtigall L, Ulm L, Flöel A. Transcranial direct current stimulation of the primary motor cortex improves word-retrieval in older adults. Front Aging Neurosci. 2014;6:253.
DOI Google Scholar
61.
Monti A, Ferrucci R, Fumagalli M, et al. Transcranial direct current stimulation (tDCS) and language. J Neurol Neurosurg Psychiatry. 2013;84(8):832–842.
DOI Google Scholar
62.
Grefkes C, Fink GR. Disruption of motor network connectivity post-stroke and its noninvasive neuromodulation. Curr Opin Neurol. 2012;25(6):670–675.
DOI Google Scholar
63.
Mazzoleni S, Sale P, Franceschini M, et al. Effects of proximal and distal robot-assisted upper limb rehabilitation on chronic stroke recovery. NeuroRehabilitation. 2013;33(1):33–39.
DOI Google Scholar
64.
Hu XL, Tong KY, Wei XJ, Rong W, Susanto EA, Ho SK. The effects of post-stroke upper-limb training with an electromyography (EMG)-driven hand robot. J Electromyogr Kinesiol. 2013;23(5):1065–1074.
DOI Google Scholar
65.
Godfrey SB, Holley RJ, Lum PS. Clinical effects of using HEXORR (hand exoskeleton rehabilitation robot) for movement therapy in stroke rehabilitation. Am J Phys Med Rehabil. 2013;92(11):947–958.
DOI Google Scholar
66.
Koopman B, van Asseldonk EH, van der Kooij H. Selective control of gait subtasks in robotic gait training: foot clearance support in stroke survivors with a powered exoskeleton. J Neuroeng Rehabil. 2013;10:3.
DOI Google Scholar
67.
Klamroth-Marganska V, Blanco J, Campen K, et al. Three-dimensional, task-specific robot therapy of the arm after stroke: a multicentre, parallel-group randomised trial. Lancet Neurol. 2014;13(2):159–166.
DOI Google Scholar
68.
Hochberg LR, Bacher D, Jarosiewicz B, et al. Reach and grasp by people with tetraplegia using a neurally controlled robotic arm. Nature. 2012;485(7398):372–375.
DOI Google Scholar
69.
Huang H, Chen L, Sanberg P. Cell therapy from bench to bedside translation in CNS neurorestoratology era. Cell Med. 2010;1(1):15–46.
DOI Google Scholar
70.
Shehadah A, Chen J, Pal A, et al. Human placenta-derived adherent cell treatment of experimental stroke promotes functional recovery after stroke in young adult and older rats. PLoS One. 2014;9(1):e86621.
DOI Google Scholar
71.
Sun C, Sun H, Wu S, et al. Conditional ablation of neuroprogenitor cells in adult mice impedes recovery of poststroke cognitive function and reduces synaptic connectivity in the perforant pathway. J Neurosci. 2013;33(44):17314–17325.
DOI Google Scholar
72.
Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol. 2012;11(4):369–380.
DOI Google Scholar
73.
Daadi MM, Li Z, Arac A, et al. Molecular and magnetic resonance imaging of human embryonic stem cell-derived neural stem cell grafts in ischemic rat brain. Mol Ther. 2009;17:1282–1291.
DOI Google Scholar
74.
Bühnemann C, Scholz A, Bernreuther C, et al. Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. Brain. 2006;129:3238–3248.
DOI Google Scholar
75.
Hayashi J, Takagi Y, Fukuda H, et al. Primate embryonic stem cell-derived neuronal progenitors transplanted into ischemic brain. J Cereb Blood Flow Metab. 2006;26:906–914.
DOI Google Scholar
76.
Chen SJ, Chang CM, Tsai SK, et al. Functional improvement of focal cerebral ischemia injury by subdural transplantation of induced pluripotent stem cells with fibrin glue. Stem Cells Dev. 2010;19:1757–1767.
DOI Google Scholar
77.
Zhang ZG, Jiang Q, Zhang R, et al. Magnetic resonance imaging and neurosphere therapy of stroke in rat. Ann Neurol. 2003;53:259–263.
DOI Google Scholar
78.
Kuroda S, Shichinohe H, Houkin K, Iwasaki Y. Autologous bone marrow stromal cell transplantation for central nervous system disorders – recent progress and perspective for clinical application. J Stem Cell Regen Med. 2011;7:1–12.
DOI Google Scholar
79.
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–736.
DOI Google Scholar
80.
Zhang L, Li Y, Romanko M, et al. Different routes of administration of human umbilical tissue-derived cells improve functional recovery in the rat after focal cerebral ischemia. Brain Res. 2012;1489:104–112.
DOI Google Scholar
81.
Janowski M, Lyczek A, Engels C, et al. Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation. J Cereb Blood Flow Metab. 2013;33(6):921–927.
DOI Google Scholar
82.
Byun JS, Kwak BK, Kim JK, Jung J, Ha BC, Park S. Engraftment of human mesenchymal stem cells in a rat photothrombotic cerebral infarction model: comparison of intra-arterial and intravenous infusion using MRI and histological analysis. J Korean Neurosurg Soc. 2013;54(6):467–476.
DOI Google Scholar
83.
Ruan GP, Han YB, Wang TH, et al. Comparative study among three different methods of bone marrow mesenchymal stem cell transplantation following cerebral infarction in rats. Neurol Res. 2013;35(2):212–220.
DOI Google Scholar
84.
Yang B, Migliati E, Parsha K, et al. Intra-arterial delivery is not superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke. Stroke. 2013;44(12):3463–3472.
DOI Google Scholar
85.
Wei N, Yu SP, Gu X, et al. Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. Cell Transplant. 2013;22:977–991.
DOI Google Scholar
86.
Barbosa da Fonseca LM, Battistella V, de Freitas GR, et al. Early tissue distribution of bone marrow mononuclear cells after intra-arterial delivery in a patient with chronic stroke. Circulation. 2009;120(6):539–541.
DOI Google Scholar
87.
Correa PL, Mesquita CT, Felix RM, et al. Assessment of intra-arterial injected autologous bone marrow mononuclear cell distribution by radioactive labeling in acute ischemic stroke. Clin Nucl Med. 2007; 32(11):839–841.
DOI Google Scholar
88.
Chang DJ, Oh SH, Lee N, et al. Contralaterally transplanted human embryonic stem cell-derived neural precursor cells (ENStem-A) migrate and improve brain functions in stroke-damaged rats. Exp Mol Med. 2013;15(45):e53.
DOI Google Scholar
89.
Dai J, Li SQ, Qiu YM, et al. Migration of neural stem cells to ischemic brain regions in ischemic stroke in rats. Neurosci Lett. 2013;552: 124–128.
DOI Google Scholar
90.
Shichinohe H, Yamauchi T, Saito H, Houkin K, Kuroda S. Bone marrow stromal cell transplantation enhances recovery of motor function after lacunar stroke in rats. Acta Neurobiol Exp (Wars). 2013;73(3):354–363.
Google Scholar
91.
Cai H, Zhang Z, Yang GY. Preconditioned stem cells: a promising strategy for cell-based ischemic stroke therapy. Curr Drug Targets. 2014;15(8):771–779.
DOI Google Scholar
92.
Yu SP, Wei Z, Wei L. Preconditioning strategy in stem cell transplantation therapy. Transl Stroke Res. 2013;4(1):76–88.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Published: 23 March 2015
Issue date: December 2015

Copyright

© 2015 The Author(s).

Acknowledgements

The authors are very appreciative for the modification by Professor Michael Chopp from the Department of Neurology at the Henry Ford Hospital, Detroit, MI, USA.

Rights and permissions

© 2015 Qiao et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Return